Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study.
Nijjar JS, Abbott-Banner K, Alvarez Y, Aston N, Bass D, Bentley JH, Ellis J, Ellson C, Emery EC, Feeney M, Fernando D, Inman D, Kaur R, Modis LK, Munoz Vicente S, Muya C, Nistala K, Panoilia E, Ray R, Siederer S, Smith JE, Weir L, Wisniacki N. Nijjar JS, et al. Among authors: wisniacki n. Ann Rheum Dis. 2024 Oct 17:ard-2023-225434. doi: 10.1136/ard-2023-225434. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39419538 Free article.
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. Among authors: wisniacki n. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases.
Vetrano S, Bouma G, Benschop RJ, Birngruber T, Costanzo A, D'Haens GRAM, Frasca L, Hillenbrand R, Iversen L, Johansen C, Kaser A, Koenen HJPM, Noehammer C, Peyrin-Biroulet L, Raes J, Ricotti L, Rosenstiel P, Satagopam VP, Schreiber S, Vermeire S, Wollenberg A, Weidinger S, Ziemek D, Danese S; ImmUniverse Consortium. Vetrano S, et al. Front Immunol. 2022 Nov 9;13:1002629. doi: 10.3389/fimmu.2022.1002629. eCollection 2022. Front Immunol. 2022. PMID: 36439150 Free PMC article.
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study.
Clark KEN, Csomor E, Campochiaro C, Galwey N, Nevin K, Morse MA, Teo YV, Freudenberg J, Ong VH, Derrett-Smith E, Wisniacki N, Flint SM, Denton CP. Clark KEN, et al. Among authors: wisniacki n. Lancet Rheumatol. 2022 Jun 23;4(7):e507-e516. doi: 10.1016/S2665-9913(22)00094-7. eCollection 2022 Jul. Lancet Rheumatol. 2022. PMID: 36404995 Free PMC article.
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
Denton CP, Del Galdo F, Khanna D, Vonk MC, Chung L, Johnson SR, Varga J, Furst DE, Temple J, Zecchin C, Csomor E, Lee A, Wisniacki N, Flint SM, Reid J. Denton CP, et al. Among authors: wisniacki n. Rheumatology (Oxford). 2022 Dec 23;62(1):234-242. doi: 10.1093/rheumatology/keac300. Rheumatology (Oxford). 2022. PMID: 35583273 Free PMC article. Clinical Trial.
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.
Jimenez-Royo P, Bombardieri M, Ciurtin C, Kostapanos M, Tappuni AR, Jordan N, Saleem A, Fuller T, Port K, Pontarini E, Lucchesi D, Janiczek R, Galette P, Searle G, Patel N, Kershaw L, Gray C, Ratia N, van Maurik A, de Groot M, Wisniacki N, Bergstrom M, Tarzi R. Jimenez-Royo P, et al. Among authors: wisniacki n. Rheumatology (Oxford). 2021 May 14;60(5):2396-2408. doi: 10.1093/rheumatology/keaa624. Rheumatology (Oxford). 2021. PMID: 33221921 Free PMC article.
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B, van Maurik A, Inman D, Oliveira J, McLaughlin R, Gittelman RM, Roep BO, Gillard P, Hilbrands R, Gorus F, Mathieu C, Van de Velde U, Wisniacki N, Napolitano A. Keymeulen B, et al. Among authors: wisniacki n. Diabetologia. 2021 Feb;64(2):313-324. doi: 10.1007/s00125-020-05317-y. Epub 2020 Nov 4. Diabetologia. 2021. PMID: 33145642 Free PMC article. Clinical Trial.
Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781.
Ellis J, J B Marks D, Srinivasan N, Barrett C, Hopkins TG, Richards A, Fuhr R, Albayaty M, Coenen M, Liefaard L, Leavens K, Nevin KL, Tang S, Hughes SA, Fortunato L, Edwards K, Cui Y, Anselm R, Delves CJ, Charles E, Feeney M, Webb TM, Brett SJ, Schmidt TS, Stone J, Savage COS, Wisniacki N, Tarzi RM. Ellis J, et al. Among authors: wisniacki n. Clin Pharmacol Ther. 2021 May;109(5):1293-1303. doi: 10.1002/cpt.2091. Epub 2020 Nov 24. Clin Pharmacol Ther. 2021. PMID: 33113155 Free PMC article. Clinical Trial.
21 results